(Q39662085)

English

The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells

scientific article published on August 30, 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

author name string

J. Dhillon

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20802512

3 July 2024

A. Astanehe

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20802512

3 July 2024

C. Lee

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20802512

3 July 2024

A. Fotovati

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20802512

3 July 2024

K. Hu

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20802512

3 July 2024

S. E. Dunn

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20802512

3 July 2024

language of work or name

0 references

publication date

30 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

full work available at URL

https://www.nature.com/articles/onc2010365.pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20802512

3 July 2024

https://www.nature.com/articles/onc2010365.pdf

Portable Document Format

1 reference

10.1038/ONC.2010.365

https://api.crossref.org/works/10.1038/ONC.2010.365

3 July 2024

https://www.nature.com/articles/onc2010365

1 reference

10.1038/ONC.2010.365

https://api.crossref.org/works/10.1038/ONC.2010.365

3 July 2024

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

47

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

6294-6300

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Prospective identification of tumorigenic breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.365

21 January 2018

The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.365

21 January 2018

Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.365

21 January 2018

Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.365

21 January 2018

Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.365

21 January 2018

Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.365

21 January 2018

HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.365

21 January 2018

Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.365

21 January 2018

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.365

21 January 2018

CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.365

21 January 2018

Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.365

21 January 2018

Targeted cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.365

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.365

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.365

21 January 2018

Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.365

21 January 2018

Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.365

21 January 2018

Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.365

21 January 2018

Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.365

21 January 2018

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.365

21 January 2018

Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.365

21 January 2018

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.365

31 March 2020

Identifiers

10.1038/ONC.2010.365

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39662085&oldid=2227231312"